Variagenics Close to Closing Big Pharma Collaboration; Promises Colon Cancer Diagnostics by End 02 | GenomeWeb

SAN FRANCISCO, Jan. 9 - Variagenics is in late-stage negotiations with at least one major pharmaceutical company to strike a pharmacogenomics-based research collaboration, the company's president and CEO said here on Wednesday.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.